Early access
Sign in
Taking peoplePhase 3

Tests JNJ-77242113 in adults with moderate to severe plaque psoriasis

Tests JNJ-77242113 against a placebo in adults with moderate to severe plaque psoriasis.

Key facts

Who runs it
Janssen - Cilag International
Where
Cagliari, Ferrara, Milan, Naples, and Novara, ItalySee the 5 sitesAlso in 5 other countries, 58 sites
Registry title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Status
Recruiting
Phase
Phase 3
People taking part
320 people, planned
Started
18 Jan 2024
Expected to end
15 Jun 2027
Type of study
Interventional
Record updated
16 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe plaque psoriasis. It tests JNJ-77242113 against a placebo and against deucravacitinib.

Age
18 years or older
Sex
All sexes can join
Disease stage
Plaque psoriasis, with or without psoriatic arthritis (PsA), diagnosed at least 26 weeks before the first study treatment. Skin area affected (BSA) 10% or more, PASI score 12 or more, and IGA score 3 or more, at screening and at baseline.

Main reasons for not taking part

  • A form of psoriasis that is not plaque psoriasis
  • Psoriasis caused by a drug right now
  • Severe, worsening or uncontrolled kidney, liver, heart, blood vessel, lung, stomach and bowel, hormone, nerve, blood, rheumatic, mental health or metabolic problems
  • Known allergy or intolerance to JNJ-77242113, deucravacitinib or any ingredient of the study treatment
  • Major surgery within 8 weeks before screening, not fully recovered, or planned during the trial

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • ≥18 years of age at the screening visit
  • Diagnosis of plaque psoriasis, with or without PsA, for at least 26 weeks prior to the first administration of study intervention
  • Total BSA ≥10% at screening and baseline
  • Total PASI ≥12 at screening and baseline
  • Total IGA ≥3 at screening and baseline

Who cannot take part

  • Current drug-induced psoriasis
  • Major surgical procedure, within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
  • A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention
  • Nonplaque form of psoriasis

Where in Italy

Also in 5 other countries, 58 sites

  • Presidio Ospedaliero San Giovanni Di DioCagliari, ItalyNo longer taking part
  • University Hospital Of FerraraFerrara, ItalyNo longer taking part
  • Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyNo longer taking part
  • Azienda Ospedaliera Universitaria Federico II Di NapoliNaples, ItalyNo longer taking part
  • Azienda Ospedaliero Universitaria Maggiore della CaritàNovara, ItalyNo longer taking part

About the trial

What the trial wants to find out

To evaluate the efficacy of JNJ-77242113 compared with placebo in participants with moderate to severe plaque psoriasis.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Plain-language title
Tests JNJ-77242113 in adults with moderate to severe plaque psoriasisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 July 2026